Take the Zacks Approach to Beat the Markets: Honda Motor, Accenture, CACI in Focus

For the week ended October 23, the Nasdaq fell 0.7% and the S&P 500 declined 0.5%, while the Dow rose 0.4%; technology stocks faced selling amid questions about AI investment returns and Middle East tensions lifted oil prices, reviving inflation and rate concerns. The article mainly promotes Zacks research, citing selected stock and model-portfolio returns, including CACI’s 31.9% and Ulta Beauty’s 30.7% gains over 12 weeks, while noting that the ECAP portfolio returned -4.7% in 2026 through September 30 versus the S&P 500’s +12.75%. Overall investor sentiment was described as cautious despite generally supportive corporate earnings.

Analysis

This is marketing built around backward-looking winners, not evidence of a durable earnings inflection. The cited rank upgrades and portfolio returns do not establish that revisions caused the moves, nor do they control for selection, valuation, or risk; several model portfolios materially lagged the broad market over the periods shown. Treat the sharp recent gains in ACN, CACI and ULTA as positioning/price information, not fresh fundamental confirmation.

Near term (days to weeks), the market’s more actionable signal is sensitivity to AI capex returns, funding costs, oil and rates. Upcoming large-cap technology results and Fed communication could quickly reset duration-sensitive multiples. Over 1–3 months, the key discriminator is whether reported guidance and estimate revisions validate the recent winners; a quantitative rank alone is insufficient. Over 6–18 months, AI-related consulting demand may benefit ACN if customers move from experimentation to implementation, but could also face delayed discretionary projects or pricing pressure. CACI’s government-demand exposure is a different earnings driver; grouping it with consumer and technology winners obscures distinct risks.

Contrarian read: the defensive label is not a reliable hedge—ECAP’s reported underperformance illustrates that lower earnings variability does not prevent relative drawdowns when market leadership narrows. With no valuation, estimate-revision magnitude, or forward guidance supplied, there is no defensible basis to chase the named outperformers or short them solely on the rally.

Key Decisions for Investors

• No immediate trade from the article’s performance tables. Do not add ACN, CACI or ULTA on trailing returns alone; first verify current valuation, forward estimates, and whether revisions are broad-based or concentrated in a single period.
• Set an earnings watch on ACN: a conditional long only if guidance or estimate revisions confirm demand conversion from AI pilots to paid implementation. Falsify the thesis on weaker bookings/guidance or evidence that clients are delaying discretionary work; avoid sizing it as a defensive proxy.
• Treat CACI as a separate catalyst-driven exposure rather than a portfolio “winner”: check contract awards, funding/appropriation signals and guidance before acting. A material deterioration in funded backlog or outlook would invalidate the recent-momentum case.
• Reassess risk after major technology earnings and the Fed meeting: if AI capex plans rise without credible return evidence, favor reducing crowded AI-duration exposure over rotating mechanically into the article’s past winners; if earnings conversion and rates are supportive, that hedge case weakens.